Cancer is the leading cause of death in dogs over 10 years of age, affecting approximately 1 in 4 dogs at some point in their lives. The welfare challenges posed by canine cancer span diagnosis, treatment decision-making, pain management, and end-of-life care — each with profound implications for dog welfare and owner-veterinarian relationships.
Common Cancers and Their Welfare Impacts
Lymphoma, mast cell tumors, osteosarcoma, hemangiosarcoma, and transitional cell carcinoma are among the most common canine cancers. Each presents distinct welfare challenges. Osteosarcoma — bone cancer — causes severe, progressive pain before diagnosis and treatment. Its most common site (distal radius) is often detectable only after significant bone destruction has occurred. Hemangiosarcoma, frequently affecting the spleen, often presents with acute collapse from internal hemorrhage, with minimal welfare warning signs preceding life-threatening crisis.
Lymphoma, while often initially responsive to chemotherapy, causes systemic illness including lymph node enlargement, lethargy, and progressive immunosuppression. Treatment-related side effects — nausea, vomiting, immunosuppression — must be balanced against the welfare benefit of disease control.
Treatment Decision Welfare Framework
Canine cancer treatment decisions require explicit welfare frameworks. Veterinary oncologists and general practitioners must communicate clearly with owners about: the likely disease trajectory without treatment; the realistic welfare-related outcomes with treatment (probability of remission, duration, side effect profile); and the quality of life implications for the individual dog given their personality, breed, and home circumstances.
Aggressive treatment that achieves extended survival at the cost of significant side-effect burden may not maximize welfare, particularly in stoic dogs whose pain and discomfort may be underreported to owners. Welfare-oriented treatment planning prioritizes quality of life metrics alongside survival duration.
Pain Management
Pain management in canine cancer patients has advanced significantly with the recognition that chronic cancer pain is a major welfare issue. Multimodal analgesia — combining NSAIDs, opioids, gabapentinoids, and adjunctive therapies — provides superior pain control to single-agent approaches. Regular pain reassessment using validated tools (Glasgow Composite Pain Scale, Helsinki Chronic Pain Index) guides dose adjustment and treatment escalation.
Quality of Life Assessment
Quality of life assessment tools help owners monitor their dogs' welfare through cancer and treatment. The HHHHHMM scale provides a structured framework for tracking hurt, hunger, hydration, hygiene, happiness, mobility, and the overall ratio of good to bad days. Regular veterinary quality of life consultations support owners in making timely, welfare-focused decisions including about euthanasia timing.